The 10th Annual Conference of the American Society of Health Economists (ASHEcon) to be held at the Marriott Wardman Park Hotel in Washington, DC from June 20-23, 2021 has opened the call for abstracts. The following submission types will be solicited in the conference's 18 program […]
Latest Stories
Pharmaceuticals Purchasing: Lessons From Other Countries
Dr. James Robinson of UC Berkeley cautions against the widening gulf and conflict between the increasing prices set by drugmakers and the increasingly strict access criteria set by insurers in the US. In his latest article, Dr. Robinson describes how the UK, Germany, France, Australia, Norway, and […]
For Shame: Congress Accuses Novartis, Amgen and Mallinckrodt of Price-Gouging
Amgen, Mallinckrodt, and Novartis are now in the same boat as Celgene and Teva. A congressional probe released several reports concluding the drugmakers relied on regular price increases to meet their sales targets and quash competition so they could retain monopoly pricing. The House Committee on […]
MMIT Announces 2020 Directory of Health Plans
Getting accurate payer and health plan enrollment data in a timely fashion is difficult; understanding the impact of health plan dynamics on your business is even more so. The 2020 Directory of Health Plans aims to empower your planning and inform your analyses by delivering up-to-date, […]
Deomcrats Take Pharma Executives to Task Over Excessive Price Hikes
Pharma industry executives have long justified increasing drug prices by pointing out the costs and risks of research and the greater number of rebates to middlemen. Yet it appears that the day of reckoning may have finally arrived. Congress recently launched a probe into the reasons for excessive […]
Hospitals and Outpatient Care Are the Primary Drivers of Sky-high US Healthcare Costs
Although drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. spends so much on health care. In 2018, the U.S. spent $10,637 per capita on health care in 2018, almost twice that spent in other developed nations. Most of the disparity (76%) is due to […]
Celgene Accused of Gouging on Revlimid Price
A congressional probe headed by the House Committee on Oversight and Government Reform released a scathing 45 page report detailing Celgene’s repeated price increases for multiple myeloma drug Revlimid. The report revealed that the drug maker hiked prices over 20 times to hit aggressive sales […]
[Webinar] Towards Greater Diversity in Clinical Trials and Health Plan Networks
Join HealthVerity on Thursday, October 15th, 2020 at 12:00 PM EDT for an in-depth discussion on the challenges of recruiting diverse populations, potential solutions to those challenges, and how to leverage race and ethnicity data attributes in a HIPAA-compliant manner. Further topics of exploration […]
Private Payers Lead Charge Toward Value-Based Care
Xtelligent Healthcare media has revealed results from a new survey showing that private payers are more likely than public payers to participate in value-based reimbursement models. The survey, Payer Perceptions of Value-Based Care, outlines the opportunities and challenges inherent in […]
SCOTUS Pick Threatens Value-based Care
The Senate is moving quickly to confirm a conservative replacement for the Supreme Court in the next month, leaving the Affordable Care Act (ACA) in peril. It remains to be seen whether certain parts of the ACA—primarily those that spurred a shift to value-based care—could survive a constitutional […]
